Tag - MGEN

Developments

miRagen cobomarsen gets FDA orphan drug designation for T-cell lymphoma

miRagen Therapeutics’ (NASDAQ:MGEN) cobomarsen was granted FDA orphan drug designation for the treatment of T-cell lymphoma. Cobomarsen, an inhibitor of microRNA-155, is being evaluated in a Phase 1 and Phase 2 trial...

July 24, 2020

Markets

Brookline starts MiRagen Therapeutics at buy; PT $6

Brookline Capital Markets initiated coverage of MiRagen Therapeutics (NASDAQ:MGEN) with a “buy” rating and 12-to-18 month price target of $6. The stock closed at $1.02 on July 20. MiRagen is working in hematologic...

July 21, 2020

Tag - MGEN

miRagen cobomarsen gets FDA orphan drug designation for T-cell lymphoma

Brookline starts MiRagen Therapeutics at buy; PT $6

General

More